Late Response to Anti-CGRP Monoclonal Antibodies in Migraine
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Paola Torelli, Stefania Proietti, Sabina Cevoli, Stefano Bonassi, for the Italian Migraine Registry study group, for the Italian Migraine Registry study group, Giulia Fiorentini Psy, Roberta Messina, Bruno Colombo, Florindo d’Onofrio, Maria Albanese, Cinzia Finocchi, Antonio Salerno, B. Mercuri, Antonio Carnevale, Francesco Bono, Fabio Frediani, Licia Grazzi, Domenico D’Amico, Massimo Filippi, Claudia Altamura, Fabrizio Vernieri, Marco Aguggia, Davide Bertuzzo, Maurizio Zucco, Laura Di Clemente, Michele Trimboli, Valentina Favoni, Paola Di Fiore
Abstract
OBJECTIVES: To assess the frequency and characteristics of late responders (>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP). METHODS: This is a multicenter (n = 16) prospective real-life study considering all consecutive adults with high-frequency or chronic migraine treated with anti-CGRP mAbs for ≥24 weeks. We defined responder patients with a ≥50% reduction from baseline in monthly migraine/headache days at weeks 9-12 and late responders as those achieving a ≥50% reduction only afterward. RESULTS: = 0.01). DISCUSSION: Half of nonresponders to anti-CGRP mAbs at 12 weeks are indeed late responders. Efficacy of anti-CGRP mAbs should be assessed at 24 weeks while treatment duration should be extended beyond 12 months.